Breast Cancer Rapid Diagnostic Test

One assay for the precise determination of Ki-67, ER, PR, and HER2.input:
output:Confident treatment decisions through definitive breast cancer subtypinginput:
output:Quantitative, observer-independent, and user-friendly testinginput:
output:Results that are delivered on the same day and with a rapid turnaround time
CE-marked IVD RT-qPCR assay for the majority of cyclers that are readily accessible

MammaTyper® accurately quantifies the expression of mRNA for HER2, ER, PR, and Ki-67.

MammaTyper® is a molecular diagnostic test that is designed to quantitatively determine the four primary biomarkers that are utilized in the subtyping of breast cancer.input:
output:Key biomarkers in the assessment of breast cancer tumors include the proliferation marker Ki-67, estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and progesterone receptor (PR).input:
output:The evaluation of the various subtypes of St. Gallen Breast Cancer, which are critical parameters for treatment decisions, is facilitated by the combination of biomarker results.input:
output:Additional informationinput:
output:MammaTyper® is a straightforward test that can be used in any pathology laboratory and provides accurate results within six hours.RNA extractioninput:
output:It is advisable to employ a validated commercial RNA extraction system or an RNA FFPE sample extraction kit in accordance with the IFU.input:
output:Mastermix preparation and distribution on a 96-well plate. Analysis of up to eight patient samples per run.input:
output:Reporting and data processinginput:
output:MammaTyper® Report Generator software that is user-friendly:input:
output:mRNA expression data export.input:
output:Evaluation and computation of outcomes.